Press Releases

bioMérieux – Information financière du 3e trimestre 2020

Croissance organique de 19,4 % à taux de change et périmètre constants au terme des 9 premiers mois : 2 266 millions d’euros de chiffre d’affaires +17,5 % de croissance à données publiées Poursuite de...

bioMérieux – Third-Quarter 2020 Business Review

Organic growth of 19.4% at constant exchange rates and scope of consolidation over the first nine months of the year: €2,266 million in sales Up 17.5% as reported Further exceptional momentum in the t...

AMSP partners with bioMérieux to facilitate supply of high-quality COVID-19 diagnostics

bioMérieux and the Africa Medical Supplies Platform (AMSP), have announced a new partnership to facilitate the supply of high-quality diagnostic solutions from the bioMérieux Pandemic Response Portfol...

First-Half 2020 Results

Organic sales growth of 15.7% in first-half 2020: €1,476 million in sales Up 15.8% as reported As expected, a mixed sales performance, with faster momentum in molecular biology solutions contrasting w...

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biothe...

Second-Quarter 2020 Business Performance Preannouncement

In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity endi...

bioMérieux issues a €200 million Euro PP bond

Marcy l’Étoile (France) - June 29, 2020 – bioMérieux, a global leader in the field of in vitro diagnostics, announces that it has successfully issued today a €200 million Euro PP new debt with a top-t...

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) is CE marked. The BIOFIRE® Respiratory Panel 2.1 plus (RP2.1pl...

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-Co...

Information concerning 2019 dividend and the bioMérieux General Shareholders’ Meeting

The Board of Directors of bioMérieux met today and decided to hold the annual General Shareholders’ Meeting behind closed doors at the bioMérieux registered office on June 30, 2020. During this meetin...

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

bioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people ...

Business & Solutions

Validation de la performance des tests sérologiques VIDAS® de bioMérieux pour le SARS-CoV-2 avant un lancement imminent

bioMérieux, acteur majeur dans le domaine du diagnostic in vitro, annonce la validation de la performance et le lancement prochain des tests sérologiques VIDAS® anti-SARS-CoV-2 pour la détection des a...

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Us...

First-Quarter 2020 Business Review

bioMérieux fully mobilized against COVID-19 epidemic Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter: €769 million in sales Up 21.5% as rep...

bioMérieux’s Annual General Meeting postponed

Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on...